Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Gilead, Arcus keep TIGIT dream alive with 27-month OS data
Gilead and Arcus’ anti-TIGIT antibody domvanalimab has been tied to median overall survival of almost 27 months.
James Waldron
Oct 13, 2025 7:05am
Sponsored
Understanding the Impact of PFAS "Forever Chemicals" on Medical Devices
Oct 13, 2025 8:00am
Excellergy emerges with $70M and ex-Dermavant CEO at the helm
Oct 13, 2025 10:50am
Sponsored
Neuroinflammation a Key Underlying Factor in Alzheimer’s Disease Risk
Oct 13, 2025 8:00am
Regeneron shares updated data on hearing loss gene therapy
Oct 12, 2025 10:18am
Moderna posts melanoma data behind decision to say 'I do' to IDO
Oct 13, 2025 5:15am
More News
Fierce Healthcare
Government shutdown updates: Reductions in force begin at HHS
Oct 13, 2025 1:25pm
Tvardi's STAT3 inhibitor flunks IPF trial amid high dropout rate
Oct 13, 2025 9:25am
Fierce Biotech Fundraising Tracker: Excellergy, Expedition & more
Oct 13, 2025 8:30am
Novo ends all cell therapy R&D, lets go of staff
Oct 10, 2025 3:30pm
See more stories